Ironwood Pharmaceuticals | IRWD - Selling And Administration Expenses


Ironwood Pharmaceuticals reported $33.33M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
Ardelyx USD 75.92M 7.69M Dec/2025
Astellas Pharma JPY 221.78B 14.94B Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Charles River Laboratories USD 196.14M 18.55M Dec/2025
Coherus Biosciences USD 15M 6.26M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.42M 456K Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Moderna USD 308M 40M Dec/2025
Myriad Genetics USD 122.3M 6.7M Dec/2025
Pacira USD 91.87M 70K Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024